Global In situ Hybridization Market Assessment, By Product Type [Consumables, Instruments, Software], By Technology [Fluorescent in situ hybridization, Chromogenic in situ hybridization], By Probe Type [DNA, RNA], By Application [Oncology, Neurology, Cytology, Immunology, Infectious Diseases, Developmental Biology, Others], By End-Users [Hospitals and Diagnostic Organizations, Clinical Research Organizations, Academics and Research Institutions, Pharmaceutical and Biotechnology Companies, Others], By Region, Opportunities and Forecast, 2017-2031F

Global in situ hybridization market size was valued at USD 1.64 billion in 2023 and is expected to reach USD 3.53 billion in 2031, with a CAGR of 10.04% for the forecast period between 2024 and 2031F. The global in situ hybridization market is highly dynamic and promising, with a robust product and favorable market tactics. The in-situ hybridization market is expected to be driven by factors such as the increasing prevalence of cancer cases and genetic disorders, the growing use of in-situ hybridization techniques in research and development, and advancements in molecular biology and genomics.

The proven efficacy of in situ hybridization techniques in diagnosing and managing diseases like cancer led to their growing adoption by healthcare professionals. Several research organizations have spent the last few years conducting extensive research to explore possibilities around in situ hybridization. It has enhanced the research and development scenario and led to significant growth in demand for such products. Hence, growing cancer cases across the globe is a major factor driving the demand for in situ hybridization techniques as it is highly efficient in detecting cancerous cells and genetic mutations. However, the high cost associated with products, lack of highly skilled professionals, and interpretation of complicated data are some hindrances in the growth of the global in situ hybridization market.

In May 2023, Bio-Techne announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope in situ hybridization (ISH) portfolio with the commercialization of RNAscope multi-omic workflow for the Standard BioTools Hyperion Imaging System.

Bio-Techne is an international life sciences firm providing innovative tools and bioactive reagents for research and clinical diagnostics. The RNAscope is considered the gold standard for in situ hybridization and is trusted by biotechnological researchers worldwide, with a rapidly growing list of over 8,000 peer-reviewed publications.

Increasing Prevalence of Cancer Cases and Genetic Disorders

In situ hybridization techniques are used in genetic testing for cancers. These techniques help to detect chromosomal changes in patients and help healthcare professionals to identify the type of cancer, based on which the treatment is designed. Due to vast applications of in situ hybridization, techniques in the diagnosis of cancers and other genetic diseases are further driving the demand in the market. Besides cancers, in situ hybridization techniques are extensively utilized to diagnose other indications like infectious, viral, and immunological diseases. The American Society of Cancer estimates that 1,958,310 new cancer cases and 609,820 cancer deaths in the United States. Cancer Research UK estimates that there will be 28 million cancer cases per year by 2040. It states that the United Kingdom’s incidence is ranked higher than 90% of the world.

Growing Research and Development

The global in situ hybridization market is positively impacted by increased research and development surrounding genome exploration, diagnostic research, and its other healthcare and life sciences applications. Over the past few decades, the human genome project has significantly contributed to the growing body of research concerning genetic explorations and life sciences research. The market is anticipated to rise significantly with the growing acceptance and application of in situ hybridization in diagnostic centers, hospitals, and institutional and academic research projects. To increase their worldwide presence, major companies in the market are pursuing tactics including new launches, mergers and acquisitions, and partnerships.

In February 2023, Molecular Instruments (MI), which is a biotech firm under the umbrella of the California Institute of Technology, launched HCR RNA-CISH. The product is expected to stimulate automated chromogenic in situ hybridization (ISH) workflows that depend on Bio-Techne’s RNAscope. According to the company, HCR RNA-CISH kits offer twice the turnaround time and half the cost of any current chromogenic in situ hybridization (CISH) method, while delivering superior performance. HCR RNA-CISH has native support for IHC codetection and is fully compatible with all popular automation platforms.

Fluorescent in Situ Hybridization (FISH) is Expected to Dominate During Forecast Period

The fluorescent in situ hybridization (FISH) technique finds a vast range of usage in the diagnosis of congenital disorders like Down’s syndrome and other genetic diseases including cancer detection and identification. The growing application areas of fluorescent in situ hybridization (FISH) and its growing demand due to the rising burden of cancers and other genetic diseases is expected to make the fluorescent in situ hybridization (FISH) segment dominate the in situ hybridization market. The COVID-19 pandemic significantly boosted in situ hybridization and several research was done on it. For instance, in September 2023, a group of researchers published a protocol in STAR protocol, for the detection of infectious SARS-CoV-2 virus at low levels through in situ hybridization techniques.

North America to Lead the Global In situ Hybridization Market

North America is anticipated to dominate the market with the highest value share regarding its significant investment in research and development, technical breakthroughs made by major companies, highly developed healthcare infrastructure, and well-established research environment in North American nations like the United States and Canada. The government's actions and initiatives to assist medication development, genetic exploration, and cancer treatment contribute to the market's growth.

Report Scope

“In situ Hybridization Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global in situ hybridization market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031F. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.

Report Attribute	Details
Base Year of the Analysis	2023
Historical Period	2017-2022
Forecast Period	2024-2031F
Projected Growth Rate	CAGR of 10.04% between 2024 and 2031F
Revenue Forecast in 2031	USD 3.53 billion
Units	Revenue in USD billion
Segments Covered	Product Type, Technology, Probe Type, Application, End-user
Regions Covered	North America, Europe, Asia-Pacific, Middle East, and Africa, South America
Key Companies Profiled	Illumina, Inc., Thermo Fisher Scientific Inc., Bio-Techne Corporation, Agilent Technologies Inc., Qiagen NV, F. Hoffmann-La Roche Ltd, Merck KGaA, PerkinElmer Inc., Myriad Genetics Inc., Leica Biosystems Nussloch GmbH, Genemed Biotechnologies, Inc.
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfill your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In this report, global in situ hybridization market has been segmented into the following categories: 

·         By Product Type

o   Consumables

o   Instruments

o   Software

·         By Technology

o   Fluorescent in situ hybridization (FISH)

o   Chromogenic in situ hybridization (CISH)

·         By Probe Type

o   DNA

o   RNA

·         By Application

o   Oncology

o   Neurology

o   Cytology

o   Immunology

o   Infectious Diseases

o   Developmental Biology

o   Others

·         By End-Users

o   Hospitals and Diagnostic Organizations

o   Clinical Research Organizations

o   Academics and Research Institutions

o   Pharmaceutical and Biotechnology Companies

o   Others

·         By Region

o    North America

o    Europe

o    Asia Pacific

o    South America

o    Middle East & Africa

Key Players Landscape and Outlook

Market players are expanding their product offerings and giving their customers access to a wide range of cutting-edge and novel products using a variety of tactics. Companies are expanding the range of products they offer to gain market share. Industry participants are using a variety of growth methods, including collaborations, mergers and acquisitions, partnerships, product launches, and development of new solutions, to bolster their position in the market.

In October 2023, Ikonisys SA partnered with Biocare Medical to expand the FISH diagnostic product portfolio. Biocare Medical is a leading firm providing immunohistochemistry (IHC) and Fluorescent in situ hybridization (FISH) tools and reagents while Ikonisys SA specializes in early and accurate detection of cancer through its unique fully automated solution for medical diagnostic labs. This partnership focuses on expanding the global distribution of products of Ikonisys SA, especially, the low-volume Ikoniscope20 and high-volume Ikoniscope20max. Earlier, Biocare Medical acquired Empire Genomics to expand its offering to include over 1 million FISH probes.

Key Players Operating in Global In Situ Hybridization Market are:

·         Illumina, Inc.,

·         Thermo Fisher Scientific Inc.

·         Bio-Techne Corporation

·         Agilent Technologies Inc.

·         Qiagen NV

·         F. Hoffmann-La Roche Ltd

·         Merck KGaA

·         PerkinElmer Inc.

·         Myriad Genetics Inc.

·         Leica Biosystems Nussloch GmbH

·         Genemed Biotechnologies, Inc.

Markets and Data’s report answers the following questions:

·         What is the current and future market size of the product/service in question globally or specific to different countries?

·         How are the markets divided into different product/service segments and the market size and growth of each segment?

·         What is the market potential of different product segments and their investment case?

·         How are the markets predicted to develop in the future and what factors will drive or inhibit growth?

·         What is the business environment and regulatory landscape specific to the product/service?

If you can't find what you're searching for or have any custom requirements for global in situ hybridization market, you may approach our team at info@marketsandata.com